A New Jersey-based biotech company is turning heads on Tuesday after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201.

To read the full story on AllPennyStocks.com, click here.

Grafico Azioni VYNE Therapeutics (NASDAQ:VYNE)
Storico
Da Feb 2025 a Mar 2025 Clicca qui per i Grafici di VYNE Therapeutics
Grafico Azioni VYNE Therapeutics (NASDAQ:VYNE)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di VYNE Therapeutics